<DOC>
	<DOC>NCT01572688</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and effectiveness of melphalan for injection for autologous stem cell transplant in multiple myeloma</brief_summary>
	<brief_title>Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients with greater or equal to 18 years, with a upper age limit of 65 years are eligible. Multiple myeloma patients, symptoms conform to diagnosis of multiple myeloma of IMWG2003/WHO2008 criteria. Patients with responsive disease after induction therapy not more than 6 courses of treatment A complete response A very good partial response A partial response At least 4 weeks long from last cytotoxic treatment(exclude Bortezomib, thalidomide, dexamethasone); Eastern Cooperative Oncology Group (ECOG) scored 0 or 1 Patient has an absolute neutrophil count of ≥1.5×109/L and platelet count≥80×109/L; Calculated creatinine clearance ＞50ml/min by CockcroftGault formula or collect urine within 24 hours. Patient with a total bilirubin ≤1.5 times of normal upper limit, AST,ALT≤2.5times of normal upper limit; Cardiopulmonary function is adequate to conduct autologous stem cell transplant. Ratio of body weight and ideal body weight ＜175%; All patients should have a life expectancy of more than 12 weeks Signed informed consent form voluntarily CD34 positive hematopoietic stem cell collected ＜2.0×106/kg Patients have a psychiatric history Female subject is pregnant or breastfeeding Patients are hypersensitive to this trial product or other alkylating agents Participate of other clinical trials within the past 4 weeks Active CNS lesions Concomitant of active infection or positive of HIV antibody Concomitant of other unhealed malignancy Left ventricular ejection fraction≤50% Patients with serious thrombosis Any severe concomitant disease that will expose study subjects to unacceptable risks. Patients not suitable to enroll by investigators considerations.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>